Abstract 1312
Background
Predictive online calculators are used by clinicians as decision aids in early breast cancer (EBC). While use statistics for these calculators have not been published, as of 2017 NHS Predict was being accessed more than 20,000 times a month. These predictive tools have not had accuracy & benefit of use prospectively confirmed in EBC, yet use of calculators has been encouraged in EBC guidelines. It is important to understand the populations informing model development & validation, to understand how data bias may impact predictions in under-represented subpopulations. This work sought to elucidate the risk of bias in model development & validation for 3 online EBC calculators (NHS Predict, Adjuvant! & Cancermath), in an effort to highlight sub-populations where calculated risk & therefore treatment benefit estimates may be less reliable.
Methods
A literature search was conducted in PubMed, search terms were “predict*” “adjuvant” “breast” & “algorithm”. Results were screened for relevance to the three predictive tools under scrutiny & additional references were extracted from relevant papers. Using a modified CHARMS checklist, the relevant sections of the development & validation papers were extracted.
Results
6 development & 24 validation papers were reviewed as summarised in the TableTable:
264P
Predict | Adjuvant | Cancermath | |
---|---|---|---|
Development population size & date range | 5694 1977-2008 | 37,968 1977-2007 | 499,724 1977-2007 |
Aged <35 in development population | 2% (111) | 0 | >0.5% |
Aged >65 in development population | 32% (1781) | 0 | >17% |
Tumour size >5cm in development population | 5% (287) | 0 | 0 |
Number of validation studies | 10 | 13 | 3 |
% retrospective | 100 | 100 | 100 |
Total number of patients in validation studies | 19,864 | 19,618 | 11,203 |
Age >65 in validations | 35% (7134) | 42% (8313) | 40% (4519) |
Age <35 in validations | 16% (3235) | 8% (1518) | 9% (1007) |
Tumour size >5cm in validations | 5% (287) | 5% (1015) | 6% (634) |
Universal exclusions | Multi-focal, inflammatory, male | Multi-focal, inflammatory, male | Multi-focal, inflammatory, male |
Neoadjuvant chemotherapy not an exclusion | 1 study (121 patients) | 0 | 0 |
Overall conclusions of validation authors | Earlier versions under-predicted mortality in women <35 Poor performance in tumours >5cm. | Poor performance in general in: <35 and >65 More advanced disease Malay ethnicity Overly optimistic survival predictions across subgroups in UK population. | Poor performance in < 35 Systematically under-predicted mortality, especially for ER-negative tumours. |
Conclusions
All 3 predictive tools have under-represented groups in their development cohorts, specifically those under 35 & over 65 years old, as well as larger tumours. Validation studies consistently demonstrate worse performance in these groups. However, due to inconsistent methodology in validation studies, quantitating the summary performance within & across tools is difficult. These predictive tools should be used with caution in under-represented populations. More work is required to look at clinical utility of tools as well as their statistical performance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4546 - Efficacy and toxicity of weekly carboplatin and paclitaxel as induction or palliative treatment in advanced esophageal cancer patients
Presenter: Femke de Man
Session: Poster Display session 2
Resources:
Abstract
5908 - Perioperative chemotherapy with Docetaxel, Oxaliplatin, Fluorouracil and Leucovorin (FLOT) versus Epirubicin, Platinum and Capecitabine or Flourouracil (EOX/ECF) in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma- Safety and response data from India.
Presenter: Tanuj Chawla
Session: Poster Display session 2
Resources:
Abstract
937 - Phase II Study of Preoperative Radiotherapy Combined with S-1 plus Cisplatin in Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: OGSG1205
Presenter: Shunji Endo
Session: Poster Display session 2
Resources:
Abstract
1119 - Observational Study of the Peritoneal Washing Cytology Positive Gastric Cancer without Gross Peritoneal Metastasis Underwent Radical D2 Gastrectomy.
Presenter: Jun Eul Hwang
Session: Poster Display session 2
Resources:
Abstract
3744 - Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)
Presenter: Akira Miki
Session: Poster Display session 2
Resources:
Abstract
5091 - Multicenter Phase I/II Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (GMBH-STO-0114)
Presenter: Kathrin Heinrich
Session: Poster Display session 2
Resources:
Abstract
2891 - A phase I study of Docetaxel/Oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction
Presenter: Kei Hosoda
Session: Poster Display session 2
Resources:
Abstract
2994 - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study (Data updated)
Presenter: Mudan Yang
Session: Poster Display session 2
Resources:
Abstract
3000 - A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)
Presenter: Daisuke Takahari
Session: Poster Display session 2
Resources:
Abstract
4653 - Impact of Pembrolizumab (pembro) Versus Paclitaxel on Health-Related Quality of Life (HRQoL) in Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer That Has Progressed After First-Line Chemotherapy (KEYNOTE-061)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract